Though NCI-MATCH and Pediatric MATCH are similar in structure, they represent different approaches to oncology.
Klausner spoke with Paul Goldberg, editor and publisher of The Cancer Letter.
NCI and ECOG-ACRIN officials said the NCI-MATCH trial will keep going, continuing to match patients with treatment arms based primarily on their molecular characteristics.
The first step in the NCI-MATCH trial—deciding how many patients to screen—was a guess.
Michael Birrer named director of the University of Alabama at Birmingham Comprehensive Cancer Center
Michael Birrer, an expert in early detection and treatment of gynecologic cancers, was named director of the University of Alabama at Birmingham Comprehensive Cancer Center.
Real-world evidence is more than just another way of tracking post-market patterns in drug utilization, said Maria Koehler, vice president of oncology strategy, innovation and collaborations at Pfizer Oncology.
A group of cancer researchers is trying to conducting randomized trials aimed at maximizing the value of oncology treatment regimens.
Cary Gross, professor of medicine and of epidemiology at Yale School of Medicine, has been working with a dataset of 35,000 non-small cell lung cancer patients, looking for signs of disparities in access to PD-1 checkpoint inhibitors.
Winship Cancer Institute of Emory University earned the comprehensive cancer center designation.Effective immediately, Winship becomes the newest NCI-designated comprehensive cancer center in the nation. The number of comprehensive cancer centers now goes up to 48. There are also 14 clinical centers and seven basic research centers.Winship Cancer Institute of Emory University earned the comprehensive cancer center designation.
Steering clear of metaphors that stem from military campaigns and space travel, St. Jude Children's Research Hospital is planning to spend $7 billion over six years for an expansion of clinical and research programs.
